MCID: NNS003
MIFTS: 32

Non-Secretory Myeloma

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Non-Secretory Myeloma

MalaCards integrated aliases for Non-Secretory Myeloma:

Name: Non-Secretory Myeloma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9547
SNOMED-CT 68 277580004
UMLS 73 C0456845

Summaries for Non-Secretory Myeloma

MalaCards based summary : Non-Secretory Myeloma is related to myeloma, multiple and indolent myeloma. An important gene associated with Non-Secretory Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and ECM-receptor interaction. The drugs Lenalidomide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include skin, and related phenotype is neoplasm.

Related Diseases for Non-Secretory Myeloma

Diseases related to Non-Secretory Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 26.9 ALB B2M CD38 CD40LG CD79A FN1
2 indolent myeloma 11.0 B2M MYOM2
3 extramedullary plasmacytoma 10.9 B2M MYOM2
4 sclerosing keratitis 10.9 B2M CD79A
5 smoldering myeloma 10.9 CD79A MYOM2
6 mononeuritis of upper limb and mononeuritis multiplex 10.9 CD40LG MYOM2
7 selective igg deficiency disease 10.9 CD40LG CD79A
8 c1q nephropathy 10.9 CD40LG CD79A
9 meningovascular neurosyphilis 10.8 CD40LG CD79A
10 alpha chain disease 10.8 CD40LG CD79A
11 brill-zinsser disease 10.8 CD40LG CD79A
12 exudative glomerulonephritis 10.8 CD40LG CD79A
13 salpingo-oophoritis 10.8 CD40LG CD79A
14 early yaws 10.8 CD40LG CD79A
15 ventilation pneumonitis 10.8 CD40LG CD79A
16 chronic interstitial cystitis 10.8 CD40LG CD79A
17 axillary adenitis 10.8 CD40LG CD79A
18 trichostrongyloidiasis 10.8 CD40LG CD79A
19 subacute bacterial endocarditis 10.8 CD40LG CD79A
20 heterophyiasis 10.8 CD40LG CD79A
21 immunoglobulin g deficiency 10.8 CD40LG CD79A
22 orbital granuloma 10.8 CD40LG CD79A
23 transient hypogammaglobulinemia of infancy 10.8 CD40LG CD79A
24 hyperglobulinemic purpura 10.8 CD40LG CD79A
25 gastroduodenitis 10.8 CD40LG CD79A
26 bacterial conjunctivitis 10.8 CD40LG CD79A
27 heavy chain disease 10.8 CD40LG CD79A
28 ophthalmia neonatorum 10.8 CD40LG CD79A
29 immunoglobulin a deficiency 1 10.8 CD40LG CD79A
30 parotid disease 10.8 CD40LG CD79A
31 cerebral arteritis 10.8 CD40LG CD79A
32 murray valley encephalitis 10.8 CD40LG MYOM2
33 selective immunoglobulin deficiency disease 10.8 CD40LG CD79A
34 geniculate herpes zoster 10.8 CD40LG CD79A
35 cardiovascular syphilis 10.8 CD40LG SMUG1
36 erythema elevatum diutinum 10.8 CD40LG CD79A
37 sporotrichosis 10.8 CD40LG CD79A
38 fallopian tube disease 10.8 CD40LG CD79A
39 hyperimmunoglobulin syndrome 10.8 CD40LG CD79A
40 congenital syphilis 10.8 CD40LG CD79A
41 monoclonal paraproteinemia 10.8 CD40LG CD79A
42 salpingitis 10.8 CD40LG CD79A
43 ocular toxoplasmosis 10.8 CD40LG CD79A
44 dysgammaglobulinemia 10.8 CD40LG CD79A
45 congenital hypogammaglobulinemia 10.8 CD40LG CD79A
46 acute maxillary sinusitis 10.8 CD40LG CD79A
47 spinocerebellar ataxia, autosomal recessive 10 10.8 CD40LG CD79A
48 parasitic ichthyosporea infectious disease 10.8 CD40LG CD79A
49 cd40 ligand deficiency 10.8 CD40LG CD79A
50 rhinosporidiosis 10.8 CD40LG CD79A

Graphical network of the top 20 diseases related to Non-Secretory Myeloma:



Diseases related to Non-Secretory Myeloma

Symptoms & Phenotypes for Non-Secretory Myeloma

MGI Mouse Phenotypes related to Non-Secretory Myeloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALB B2M CD79A FN1 SMUG1

Drugs & Therapeutics for Non-Secretory Myeloma

Drugs for Non-Secretory Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 3 191732-72-6 216326
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
3
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
4 Pomalidomide Approved Phase 3,Phase 2 19171-19-8
5 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
6 interferons Phase 3
7 glucocorticoids Phase 3,Phase 2
8
protease inhibitors Phase 3,Phase 2,Phase 1
9 Gastrointestinal Agents Phase 3,Phase 2
10 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
11 Hormone Antagonists Phase 3,Phase 2
12 Angiogenesis Inhibitors Phase 3,Phase 2
13 Hormones Phase 3,Phase 2
14 Angiogenesis Modulating Agents Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
16 Peripheral Nervous System Agents Phase 3,Phase 2
17 Anti-Bacterial Agents Phase 3,Phase 2
18 Immunosuppressive Agents Phase 3,Phase 2
19 Anti-Infective Agents Phase 3,Phase 2
20 Antiemetics Phase 3,Phase 2
21 Anti-Inflammatory Agents Phase 3,Phase 2
22 BB 1101 Phase 3,Phase 2
23 Autonomic Agents Phase 3,Phase 2
24 Antineoplastic Agents, Hormonal Phase 3,Phase 2
25
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
26
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
29 Alkylating Agents Phase 2
30 Histone Deacetylase Inhibitors Phase 2
31 Vaccines Phase 2
32 Antirheumatic Agents Phase 2
33 Antineoplastic Agents, Alkylating Phase 2
34 Prednisolone acetate Phase 2
35 Methylprednisolone acetate Phase 2
36 Methylprednisolone Hemisuccinate Phase 2
37 Neuroprotective Agents Phase 2
38 Prednisolone hemisuccinate Phase 2
39 Prednisolone phosphate Phase 2
40 Protective Agents Phase 2
41 Bendamustine Hydrochloride Phase 2
42
Sorafenib Approved, Investigational Phase 1 284461-73-0 216239 406563
43 Ixazomib Approved, Investigational Phase 1 1072833-77-2
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 1 98-92-0 936
45
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1 77-92-9 311
47
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
49 Micronutrients Phase 1
50 Chelating Agents Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) Completed NCT00732641 Phase 3 Peginterferon
2 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
3 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multi Completed NCT01311687 Phase 3 pomalidomide;dexamethasone
4 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 2 panobinostat;bortezomib;dexamethasone
5 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma Completed NCT02011113 Phase 2 Pomalidomide;Dexamethasone
6 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
7 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Completed NCT01849848 Phase 2 SyB L-0501
8 Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma Terminated NCT01179490 Phase 2 SyB L-0501;prednisolone
9 Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Completed NCT00303797 Phase 1 17-N-allylamino-17-demethoxygeldanamycin/bortezomib;sorafenib tosylate
10 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed NCT00963820 Phase 1 Ixazomib citrate

Search NIH Clinical Center for Non-Secretory Myeloma

Genetic Tests for Non-Secretory Myeloma

Anatomical Context for Non-Secretory Myeloma

MalaCards organs/tissues related to Non-Secretory Myeloma:

41
Skin

Publications for Non-Secretory Myeloma

Articles related to Non-Secretory Myeloma:

(show all 16)
# Title Authors Year
1
Non-Secretory Myeloma: Ready for a new Definition? ( 28894562 )
2017
2
Non-Secretory Myeloma, Diagnosed on Renal Biopsy as Cast Nephropathy. ( 27504298 )
2016
3
A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. ( 26003102 )
2015
4
Non-secretory myeloma: clinical and biologic implications. ( 24282995 )
2013
5
Non-secretory myeloma: one, two, or more entities? ( 24282994 )
2013
6
Non-secretory myeloma: a clinician's guide. ( 24282993 )
2013
7
Polymyositis associated with non-secretory myeloma - a case report. ( 23393512 )
2011
8
Non-secretory myeloma: a rare variant of multiple myeloma. ( 18803898 )
2008
9
Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. ( 10634653 )
2000
10
Twelve-year profile of a non-secretory myeloma with amyloidosis. ( 2282322 )
1990
11
Skin involvement in non-secretory myeloma. ( 3407670 )
1988
12
Hypercalcaemia in a patient with non-secretory myeloma. ( 3211820 )
1988
13
Non-secretory myeloma. ( 3793705 )
1986
14
Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing. ( 3926829 )
1985
15
Disseminated intravascular coagulation in a case of non-secretory myeloma. ( 6511287 )
1984
16
Intact and fragmented intracellular immunoglobulin in a case of non-secretory myeloma. ( 1123437 )
1975

Variations for Non-Secretory Myeloma

Expression for Non-Secretory Myeloma

Search GEO for disease gene expression data for Non-Secretory Myeloma.

Pathways for Non-Secretory Myeloma

Pathways related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 B2M CD38 CD40LG CD79A
2
Show member pathways
11.67 FN1 ITGAE ITGAX
3 11.5 CD38 CD79A ITGAX
4 11.06 FN1 ITGAE ITGAX
5 10.67 CD38 ITGAE ITGAX

GO Terms for Non-Secretory Myeloma

Cellular components related to Non-Secretory Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 B2M CD40LG CD79A CXCL9 ITGAE ITGAX
2 integrin complex GO:0008305 8.96 ITGAE ITGAX

Sources for Non-Secretory Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....